Business Wire

ALIBABA-CLOUD

19.3.2020 05:26:06 CET | Business Wire | Press release

Share
Alibaba Cloud Offers AI, Cloud Services to Help Battle COVID-19 Globally

Alibaba Cloud, the data intelligence backbone of Alibaba Group, said today it has offered medical personnel around the world advanced cloud-based technology applications in the fight against the COVID-19 pandemic.

The artificial intelligence-enhanced innovations are based on learnings and insights garnered during the initial outbreak of the virus.

The series of cloud-native anti-coronavirus solutions stem from joint efforts of Alibaba Cloud’s solution experts, scientists and researchers from Alibaba DAMO Academy and the technical team at DingTalk, one of the platforms UNESCO has tabbed as facilitating distance learning during the coronavirus outbreak.

While DingTalk might be better-known for supporting more than 120 million students across China with their live-streamed online classes, the team has taken it up a notch to launch DingTalk’s International Medical Expert Communication Platform , hosted on Alibaba Cloud. It provides a means of free communication for medical workers all over the world to directly contact doctors from medical institutions such as the First Affiliated Hospital of Zhejiang University and others in China, who have been on the frontline of the COVID-19 battle.

Through video conferencing and real-time AI translation into 11 languages (Arabic, Bahasa, Chinese, English, French, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), Alibaba Cloud aims to build a virtual community, inviting Chinese doctors to share their experiences and answer questions from global peers.

From Alibaba DAMO Academy, a global research initiative by Alibaba, three proven solutions are being made available via free trial for medical professionals and research institutes worldwide. Alibaba Cloud will work with local partners to deploy relevant services and solutions in accordance with local laws and regulations.

Epidemic Prediction Solution models epidemic characteristics of COVID-19 in a particular region, providing estimates of size, peak time and duration of the epidemic, as well as the spreading trends under three conditions - optimistic, neutral, and pessimistic. Based on machine learning, the algorithm was already tested on 31 provincial data in China and averaged 98% accuracy. It can serve as a reference to policymakers and medical researchers on prevention and control measures, medical resource allocation and travel advisories.

CT Image Analytics Solution is a CT image analytics technology service that can significantly improve testing accuracy and detection efficiency for diagnosing COVID-19. With deep-learning algorithms trained by data in China, the trained model can predict the probability of different pneumonia types, including the variety associated with COVID-19. It also performs computations of the proportion of lesions and the affected volume ratio to the entire lungs, by using the lung segmentation method. The whole test takes about 3 to 4 seconds to run and 15 to 16 seconds of transmission time, making it nearly 60 times faster than human detection. More than 160 hospitals in China are currently using the solution.

Genome Sequencing for Coronavirus Diagnostic Solution , an AI algorithm from Alibaba DAMO Academy and running on Alibaba Cloud, is a virus genome sequencing solution for coronavirus analytics, including viral genetic data screening, evolutionary analysis, protein structure analysis, and diagnostic reporting. It can complete the diagnosis of new coronavirus within 14 hours, which is five times faster than other available sequencing solutions in China. It can screen more than 20 people simultaneously, making the averaged time for each sample just around half an hour, much shorter than the normal two hours with the PCR method. The solution helps disease control centers, hospitals and clinics, and laboratories to address challenges such as insufficient nucleic acid detection capacity, high false-negative rates of the PCR method, and possible virus mutations.

Supporting advanced innovations during emergencies like COVID-19 requires extremely scalable supercomputing power. For this, Alibaba Cloud offers Elastic High-Performance Computing (E-HPC) Solution for Life Sciences , a cloud-native high-performance computing cluster solution designed for researchers working on life sciences applications, especially for Computational-Driven-Drug-Design (CDDD) and AI-Driven-Drug-Design (AIDDD). The solution already supports 20 research groups in China. For example, the intelligent CT diagnostic system on COVID-19 pneumonia developed by Tsinghua University can complete diagnosing in 10 seconds, and the performance of gene assembly by Sun Yat-sen University is accelerated by 25% utilizing the solution. Alibaba Cloud has also partnered with Global Health Drug Discovery Institute (GHDDI) in Beijing to launch an AI-driven-drug-discovery platform based on E-HPC.

For those looking to learn more about key lessons and experience from doctors and other medical personnel at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), the Jack Ma Foundation and Alibaba Foundation have also shared a handbook from the medical personnel covering what they’ve learned every step of the way, from screening to diagnosis and treatment of patients who contracted COVID-19. Medical personnel can download the handbook at https://covid-19.alibabacloud.com/ .

For more information about the above solutions available for global medical communities and businesses, please visit: https://www.alibabacloud.com/campaign/supports-your-business-anytime

Notes to the editors

The information in this press release should not be interpreted as offering medical advice or diagnostics, which should be given exclusively by authorized medical professionals in relevant jurisdiction. All data referred to are those as of writing of this summary, and Alibaba Cloud explicitly disclaim any warranty for accuracy or performance.

About Alibaba Cloud

Established in 2009, Alibaba Cloud (www.alibabacloud.com ), the data intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye